2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Tara Sanft, MD, assistant professor of medicine, medical director of adult survivorship for the Yale Cancer Center Survivorship Clinic, discuses advancements in HER2-positive breast cancer.
Tara Sanft, MD, assistant professor of medicine, medical director of adult survivorship for the Yale Cancer Center Survivorship Clinic, discuses advancements in HER2-positive breast cancer.
About 30% of breast cancer patients have HER2 overexpression or amplification. One of the biggest advancements in this field over the last decade was the introduction of the HER2-targeted treatment pertuzumab, says Sanft.
Pertuzumab plus trastuzumab and chemotherapy is better than trastuzumab and chemotherapy alone. Patients that have received pertuzumab, trastuzumab, and chemotherapy prior to surgery have a higher chance of achieving a pathological complete response (pCR). Patients that have a pCR have a greater chance of recovery, says Sanft.
Related Content: